Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Imarikiren hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Imarikiren hydrochloride: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Danusertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Danusertib: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
EXOC3L1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for EXOC3L1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
EXOC3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for EXOC3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Difluoroethane Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Difluoroethane: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
EXOC2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for EXOC2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Nestorone Acetate/Testosterone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Nestorone Acetate/Testosterone: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
EXOC1L Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for EXOC1L, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Afimoxifene Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Afimoxifene: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
EXOC1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for EXOC1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Depatuxizumab mafodotin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Depatuxizumab mafodotin: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
EXO5 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for EXO5, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.